Caris Life Sciences, Inc. (CAI) News
Track canonical SquawkNews coverage tagged to CAI, Caris Life Sciences, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 17 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today
The U.S. 10-year Treasury yield broke above 5% on Tuesday, and crude oil stormed past $105 a barrel, a combination that left every major U.S. equity index in the red at midday. President Donald Trump said on Truth Social
LIVE | Sep 15, 2026, 05:27 PM UTC
L
Caris Life Sciences to Present at Morgan Stanley Healthcare Conference; Investor deck posted online
Caris Life Sciences will use a new investor presentation at the Morgan Stanley 24th Annual Global Healthcare Conference and other investor meetings.Key Highlights:Original SEC Filing: Caris Life Sciences, Inc. [ CAI ] -
REGULATION | Sep 14, 2026, 08:47 PM UTC
L
UBS sets $28 Caris Life Sciences price target
UBS announced a $28.00/share price target for Caris Life Sciences.
EQUITY | Sep 09, 2026, 01:26 PM UTC
L
Caris Life Sciences launches new national commercial featuring Kevin Costner
Caris Life Sciences said it launched a new national commercial to raise awareness of early cancer detection, highlighting Caris Detect, a multi-cancer early detection blood test now available nationwide.
EQUITY | Sep 08, 2026, 10:30 AM UTC
L
Caris Life Sciences president sold stock in broker-assisted options exercise
Officer David Baxley Spetzler sold Caris Life Sciences common stock in a broker-assisted sell-to-cover of fully vested stock options. Weighted average sale prices were $24.7604, $25.3201 and $24.7552 per share.
EQUITY | Sep 04, 2026, 09:11 PM UTC
L
CAI - Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer - Click For
CAI - Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
EQUITY | Sep 02, 2026, 12:32 PM UTC
L
Caris publishes study validating AI approach to pancreatic cancer treatment selection
Caris Life Sciences said a study in npj Precision Oncology validated Caris AI Insights for first-line pancreatic cancer treatment selection, including guidance between FOLFIRINOX and gemcitabine plus nab-paclitaxel.
REGULATION | Aug 27, 2026, 12:35 PM UTC
L
Caris Life Sciences publishes npj Precision Oncology study
Caris Life Sciences published an npj Precision Oncology study on AI-guided therapy selection in pancreatic cancer, reporting longer survival.
EQUITY | Aug 27, 2026, 12:30 PM UTC
L
CA Immobilien H1 gross rental income falls 16%
CA Immobilien said its H1 gross rental income fell 16% after property sales, according to TradingView News.
EQUITY | Aug 26, 2026, 04:14 PM UTC
L
CAI reports H1 funds from operations of EUR 55.6 million
CA Immobilien reported H1 funds from operations (FFO) of EUR 55.6 million, according to TradingView News.
EARNINGS | Aug 26, 2026, 04:11 PM UTC
L
CAI reports H1 2026 FFO I of €55.6m
CAI said occupancy was stable at 94.1%, GRI fell 15.6%, and FFO I for H1 2026 came in at €55.6m.
EARNINGS | Aug 26, 2026, 04:09 PM UTC
L
CAI: Rental income and net results declined on asset sales, but balance sheet and prime focus remain strong
CAI: Rental income and net results declined on asset sales, but balance sheet and prime focus remain strong
EQUITY | Aug 26, 2026, 04:08 PM UTC
L
CA Immobilien Anlagen AG half-yearly report filed under article 125
CA Immobilien Anlagen AG said its half-yearly financial report is submitted under article 125 BörseG, per TradingView News.
EQUITY | Aug 26, 2026, 04:00 PM UTC
L
Half-yearly financial report according to article 125 BörseG
Half-yearly financial report according to article 125 BörseG
EQUITY | Aug 26, 2026, 04:00 PM UTC
L
Caris Life Sciences Raises FY2026 Sales Guidance from $1.000B-$1.020B to $1.030B-$1.040B vs $1.003B Est
Caris Life Sciences (NASDAQ: CAI ) raises FY2026 sales outlook from $1.000 billion-$1.020 billion to $1.030 billion-$1.040 billion vs $1.003 billion estimate.
EARNINGS | Aug 05, 2026, 08:25 PM UTC
L
CAI - Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
CAI - Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
EARNINGS | Aug 05, 2026, 08:06 PM UTC
L
BTIG Reiterates Buy on Caris Life Sciences, Maintains $32 Price Target
BTIG analyst Mark Massaro reiterates Caris Life Sciences (NASDAQ: CAI ) with a Buy and maintains $32 price target.
EQUITY | Jul 02, 2026, 10:23 AM UTC